Effects of a human compact anti-ErbB2 antibody on gastric cancer
Carmine Fedele1, Silvia Carvalho, Gennaro Riccio
1Dipartimento di Biologia Strutturale e Funzionale, Università di Napoli Federico II, via Cinthia, 80126, Naples, Italy.
Background:
Gastric cancer represents one of the most common causes of cancer deaths worldwide. Overexpression of ErbB2, a tyrosine kinase receptor involved in the pathogenesis of several human cancer types, has been reported also in gastric cancer. Thus, the inhibition of ErbB2 signal transduction pathways by the use of human antibodies could be a valuable strategy for the therapy of this type of cancer.
Methods:
We tested for the first time the antitumor effects on gastric cancer cells of Erb-hcAb, a novel fully human compact antibody, prepared in our laboratory, which targets a different epitope of ErbB2 with respect to trastuzumab, the only anti-ErbB2 antibody currently in clinical use for both breast and gastric cancer therapy.
Results:
Herein we demonstrate that the in vitro and in vivo growth of gastric cancer cells is efficiently inhibited by Erb-hcAb, which shows antitumor effects on the NCI-N87 cell line more potent than those observed for trastuzumab.
Conclusions:
Erb-hcAb could be a promising candidate in the immunotherapy of gastric cancer as it combines the antiproliferative effect associated with the inhibition of ErbB2 signaling on tumor target cells with the ability to induce antibody-dependent cellular cytotoxicity.
Insights
A novel human antibody, Erb-hcAb, effectively inhibits gastric cancer growth by targeting ErbB2. This antibody demonstrates superior antitumor effects compared to trastuzumab, offering a promising new avenue for gastric cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Gastric cancer is a leading cause of cancer mortality globally.
- ErbB2 receptor tyrosine kinase is implicated in gastric cancer pathogenesis.
- Targeting ErbB2 signaling with human antibodies presents a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the antitumor effects of Erb-hcAb, a novel fully human compact antibody targeting ErbB2.
- To compare the efficacy of Erb-hcAb with trastuzumab in gastric cancer models.
Main Methods:
- In vitro and in vivo testing of Erb-hcAb on gastric cancer cells (NCI-N87 cell line).
- Assessment of Erb-hcAb's mechanism of action, including ErbB2 signaling inhibition and antibody-dependent cellular cytotoxicity induction.
Main Results:
- Erb-hcAb demonstrated potent inhibition of gastric cancer cell growth both in vitro and in vivo.
- Erb-hcAb exhibited superior antitumor effects compared to trastuzumab against the NCI-N87 cell line.
Conclusions:
- Erb-hcAb is a promising candidate for gastric cancer immunotherapy.
- Erb-hcAb combines antiproliferative effects via ErbB2 signaling inhibition with antibody-dependent cellular cytotoxicity.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...